ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1853

Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome

Leah Huey1, Emily Vance1, Kofi Asare-Konadu2 and Ruth Napier3, 1Oregon Health & Science University, Portland, OR, 2Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, 3Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR

Meeting: ACR Convergence 2024

Keywords: Animal Model, Eye Disorders, Pediatric rheumatology, T Cell, TH17 Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Blau syndrome, a pediatric rheumatological disease characterized by uveitis, arthritis, and dermatitis, is caused by a single point mutation in the gene NOD2. Nod2 is an intracellular pattern recognition receptor important for host defense against infection. Recent studies show Blau mutations result in a loss of function of NOD2 resulting in diminished bacterial sensing capacity, however, how mutated NOD2 results in sterile inflammation in Blau syndrome is unknown.  We recently showed that non-mutated Nod2 functions within T cells to inhibit Th17/IL-17-mediated experimental autoimmune uveitis and arthritis. Here we sought to investigate how Blau Nod2 mutations affect autoreactive Th17 responses and experimental autoimmune uveitis (EAU) pathogenesis.

Methods: Rag1-/- mice were reconstituted with CD4 T cells isolated from naïve Nod2R314Q or wildtype (WT) mice. After 7 days of reconstitution, peripheral blood CD4 T cell expression of transcription factor, Rorγt, was quantified by flow cytometry.  One day later, EAU was induced by immunization with the human retinal antigen, interphotoreceptor retinoid binding protein (IRBP1-20), complete Freund’s adjuvant and pertussis toxin. Intraocular inflammation was assessed over time by genotype-masked clinical scoring of retinal images and histology from eyes collected on day 21 post immunization. Antigen-specific T cell responses were assessed by cytokine production via ELISA by restimulating splenocytes ex-vivo on day 21 post immunization with retinal peptide, IRBP. Data were analyzed by Mann Whitney U test, and p< 0.05 were considered significant.

Results: To study mechanisms of Blau syndrome pathogenesis our lab employs a unique knock-in mouse expressing the most common human Blau mutation, NOD2 R334Q (Nod2 R314Q). To understand how Nod2R314Q T cells control CD4 T cell mediated autoimmunity in EAU, T cell-deficient Rag1-/- mice were reconstituted with Nod2R314Q or WT CD4 T cells and uveitis was induced 7 days later. WT and Nod2R314Q T cell-recipient mice had equal T cell reconstitution as measured by CD4+ T cells in circulation at 7 days, however, Nod2R314Q T cell recipients had increased expression of the Th17-associated transcription factor, Rorγt, (15% of CD4+) compared to WT T cells (7.5% of CD4+), indicating Nod2R314Q enhances Th17 responses during non-infectious T cell homeostasis. Twenty-one days post immunization Nod2R314Q T cell recipients had more severe uveitis including increased retina (IRBP)-specific IL-17 production compared to WT T cell recipients. These data indicate that T cells expressing the Nod2R314Q mutation are sufficient to cause exacerbated Th17-mediated uveitis.

Conclusion: Our data suggest Nod2R314Q enhances Th17 immunity, and the pathogenesis of T cell mediated uveitis. This study reveals the potential role of T cells and IL-17 in Blau syndrome pathogenesis and highlights the need to investigate T cell-based therapies for Blau syndrome and other NOD2-mediated diseases.  


Disclosures: L. Huey: None; E. Vance: None; K. Asare-Konadu: None; R. Napier: None.

To cite this abstract in AMA style:

Huey L, Vance E, Asare-Konadu K, Napier R. Mutated Nod2 Enhances Pathogenic Th17 Responses That Promote Experimental Blau Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/mutated-nod2-enhances-pathogenic-th17-responses-that-promote-experimental-blau-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mutated-nod2-enhances-pathogenic-th17-responses-that-promote-experimental-blau-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology